Zoetis Inc.
General ticker "ZTS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $70.0B (TTM average)
Zoetis Inc. does not follow the US Stock Market performance with the rate: -15.7%.
Estimated limits based on current volatility of 1.3%: low 121.42$, high 124.56$
Factors to consider:
- Earnings expected soon, date: 2026-02-12 bmo
- Company included in S&P500 list
- Company pays dividends (irregularly): last record date 2025-10-31, amount 0.50$ (Y0.40%)
- Total employees count: 13800 (-2.1%) as of 2024
- US accounted for 54.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Pandemic risks, Geopolitical risks, Cybersecurity threats, Reputation and brand risks, Online business disruptions
- Current price 14.4% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [139.66$, 200.35$]
- 2025-12-31 to 2026-12-31 estimated range: [145.87$, 207.97$]
Financial Metrics affecting the ZTS estimates:
- Negative: with PPE of 27.8 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 36.65 > 18.34
- Positive: Interest expense per share per price, % of 0.32 <= 0.73
- Positive: Investing cash flow per share per price, % of -0.42 > -0.63
- Negative: negative Industry operating cash flow (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 14.92 > 6.11
- Positive: 19.41 < Shareholder equity ratio, % of 33.50 <= 42.77
Short-term ZTS quotes
Long-term ZTS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $8,080.00MM | $8,544.00MM | $9,256.00MM |
| Operating Expenses | $5,152.00MM | $5,475.00MM | $5,864.00MM |
| Operating Income | $2,928.00MM | $3,069.00MM | $3,392.00MM |
| Non-Operating Income | $-272.00MM | $-133.00MM | $-259.00MM |
| Interest Expense | $237.00MM | $258.00MM | $242.00MM |
| R&D Expense | $539.00MM | $614.00MM | $686.00MM |
| Income(Loss) | $2,656.00MM | $2,936.00MM | $3,133.00MM |
| Taxes | $545.00MM | $596.00MM | $637.00MM |
| Profit(Loss)* | $2,114.00MM | $2,344.00MM | $2,486.00MM |
| Stockholders Equity | $4,405.00MM | $4,997.00MM | $4,770.00MM |
| Inventory | $2,345.00MM | $2,564.00MM | $2,306.00MM |
| Assets | $14,925.00MM | $14,286.00MM | $14,237.00MM |
| Operating Cash Flow | $1,912.00MM | $2,353.00MM | $2,953.00MM |
| Capital expenditure | $586.00MM | $732.00MM | $655.00MM |
| Investing Cash Flow | $-883.00MM | $-777.00MM | $-315.00MM |
| Financing Cash Flow | $-904.00MM | $-3,109.00MM | $-2,660.00MM |
| Earnings Per Share** | $4.51 | $5.08 | $5.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.